Apogee Therapeutics, a Phase 1-ready biotech developing monoclonal antibodies for inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Apogee Therapeutics is developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications with high unmet need. Its two most advanced programs, APG777 and APG808, are subcutaneous extended half-life monoclonal antibodies initially being developed for AD and COPD, respectively. The company anticipates initiating a Phase 1 trial of APG777 in the 2H23, with initial data expected in mid-2024, and anticipates nominating a development candidate for its APG808 program in 2023.
The Waltham, MA-based company was founded in 2022 and plans to list on the Nasdaq under the symbol APGE. Apogee Therapeutics filed confidentially on April 28, 2023. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
